Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aurinia Pharmaceuticals I...

    NASDAQ: AUPH · Real-Time Price · USD
    8.13
    -0.05 (-0.61%)
    At close: Jun 16, 2025, 3:59 PM
    8.18
    0.55%
    After-hours: Jun 16, 2025, 07:58 PM EDT
    -0.61%
    Bid 7.49
    Market Cap 1.1B
    Revenue (ttm) 247.29M
    Net Income (ttm) 39.84M
    EPS (ttm) 0.27
    PE Ratio (ttm) 30.13
    Forward PE 10.76
    Analyst Buy
    Ask 8.35
    Volume 834,718
    Avg. Volume (20D) 1,217,161
    Open 8.25
    Previous Close 8.18
    Day's Range 8.11 - 8.29
    52-Week Range 5.20 - 10.67
    Beta 1.16

    About AUPH

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AUPH
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AUPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    +10.9%
    Aurinia Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    9 months ago
    +0.77%
    Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.
    news image

    2 weeks ago · zacks.com

    Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

    news image

    3 weeks ago · businesswire.com

    New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.

    news image

    1 month ago · benzinga.com

    Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

    Aurinia Pharmaceuticals Inc.  AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.

    news image

    1 month ago · seekingalpha.com

    Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - Preside...

    news image

    1 month ago · zacks.com

    Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates

    Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.

    news image

    1 month ago · businesswire.com

    Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.

    news image

    1 month ago · businesswire.com

    Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.

    news image

    1 month ago · businesswire.com

    Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.

    news image

    1 month ago · businesswire.com

    ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--ISS recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.

    news image

    1 month ago · seekingalpha.com

    Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

    AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 ear...

    Add to Watchlist